Literature DB >> 8989773

Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons.

A F Russo1, M S Clark, P L Durham.   

Abstract

Serotonergic neurons play key roles in modulating a wide variety of behavioral and homeostatic processes. However, there is a paucity of good model systems to study these neurons at a molecular level. In this review we will present evidence that cell lines derived from an unexpected source, thyroid parafollicular cells (PF) (also called C cells), fit the criteria for use as models for the study of serotonergic neurons. A strength of PF cell lines over other cell lines is that the parental PF cells have serotonergic properties and a neuronal potential that is consistent with their neural crest origin. Furthermore, PF cells and PF cell lines are capable of expressing the fundamental properties of serotonergic neurons, including: (1) serotonin (5-HT) biosynthesis by tryptophan hydroxylase (TPH), (2) vesicular 5-HT storage and regulated release, (3) expression of a 5-HT autoreceptor, and (4) expression of the 5-HT transporter. In this review, we will focus primarily on the serotonergic and neuronal properties of the rat CA77 PF cell line and the parental rat PF cells. The applicability of CA77 cells for molecular analyses will be described. First, their use for studies on the glucocorticoid regulation of the TPH gene will be discussed. Second, control of the calcitonin/calcitonin gene-related peptide (CT/CGRP) gene will be discussed, with particular emphasis on the application of serotonergic drugs in treating migraine headaches. These examples highlight the versatility of thyroid PF cell lines as a system for studying the control of both serotonin biosynthesis and physiological actions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8989773     DOI: 10.1007/BF02740626

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  122 in total

1.  Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex.

Authors:  M S German; J Wang; R B Chadwick; W J Rutter
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

Review 2.  The use of cell lines in neurobiology.

Authors:  U Lendahl; R D McKay
Journal:  Trends Neurosci       Date:  1990-04       Impact factor: 13.837

3.  Renal and neuronal abnormalities in mice lacking GDNF.

Authors:  M W Moore; R D Klein; I Fariñas; H Sauer; M Armanini; H Phillips; L F Reichardt; A M Ryan; K Carver-Moore; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

4.  How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors.

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

5.  Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons.

Authors:  R M Lindsay; A J Harmar
Journal:  Nature       Date:  1989-01-26       Impact factor: 49.962

Review 6.  Steroid hormone receptors: many actors in search of a plot.

Authors:  M Beato; P Herrlich; G Schütz
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

7.  Down-regulation of calcitonin gene transcription by vitamin D requires two widely separated enhancer sequences.

Authors:  S Peleg; R V Abruzzese; C W Cooper; R F Gagel
Journal:  Mol Endocrinol       Date:  1993-08

Review 8.  Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter.

Authors:  M J Owens; C B Nemeroff
Journal:  Clin Chem       Date:  1994-02       Impact factor: 8.327

9.  The cyclic AMP response element in the calcitonin/calcitonin gene-related peptide gene promoter is necessary but not sufficient for its activation by nerve growth factor.

Authors:  A Watson; D Latchman
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

10.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

Authors:  L M Mulligan; C Eng; C S Healey; D Clayton; J B Kwok; E Gardner; M A Ponder; A Frilling; C E Jackson; H Lehnert
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

View more
  7 in total

1.  Glucocorticoids differentially inhibit expression of the RET proto-oncogene.

Authors:  A Capes-Davis; S D Andrew; V J Hyland; S Twigg; D L Learoyd; T Dwight; D J Marsh; B G Robinson
Journal:  Gene Expr       Date:  1999

2.  Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation.

Authors:  P L Durham; R V Sharma; A F Russo
Journal:  J Neurosci       Date:  1997-12-15       Impact factor: 6.167

3.  Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons.

Authors:  Paul L Durham; Andrew F Russo
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 4.  Advances in the molecular characterization of tryptophan hydroxylase.

Authors:  S M Mockus; K E Vrana
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

5.  Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia.

Authors:  Oskar Koperek; Astrid Prinz; Christian Scheuba; Bruno Niederle; Klaus Kaserer
Journal:  Virchows Arch       Date:  2009-05-30       Impact factor: 4.064

6.  Calcium receptor-induced serotonin secretion by parafollicular cells: role of phosphatidylinositol 3-kinase-dependent signal transduction pathways.

Authors:  Kuo-peing Liu; Andrew F Russo; Shu-chi Hsiung; Mella Adlersberg; Thomas F Franke; Michael D Gershon; Hadassah Tamir
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

7.  Alternative splicing of the neurofibromatosis type 1 pre-mRNA is regulated by the muscleblind-like proteins and the CUG-BP and ELAV-like factors.

Authors:  Victoria A Fleming; Cuiyu Geng; Andrea N Ladd; Hua Lou
Journal:  BMC Mol Biol       Date:  2012-12-10       Impact factor: 2.946

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.